Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSOFEU, Casimir
dc.contributor.authorEMURA, T.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRONDEAU, Virginie
dc.date.accessioned2020-07-13T13:26:10Z
dc.date.available2020-07-13T13:26:10Z
dc.date.issued2019-07-20
dc.identifier.issn1097-0258 (Electronic) 0277-6715 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/10445
dc.description.abstractEnA surrogate endpoint can be used instead of the most relevant clinical endpoint to assess the efficiency of a new treatment. Before being used, a surrogate endpoint must be validated based on appropriate methods. Numerous validation approaches have been proposed with the most popular used in a context of meta-analysis, based on a two-step analysis strategy. For two failure-time endpoints, two association measurements are usually used, Kendall's tau at the individual level and the adjusted coefficient of determination ( R t r i a l , a d j 2 ) at the trial level. However, R t r i a l , a d j 2 is not always available due to model estimation constraints. We propose a one-step validation approach based on a joint frailty model, including both individual-level and trial-level random effects. Parameters have been estimated using a semiparametric penalized marginal log-likelihood method, and various numerical integration approaches were considered. Both individual- and trial-level surrogacy were evaluated using a new definition of Kendall's tau and the coefficient of determination. Estimators' performances were evaluated using simulation studies and satisfactory results were found. The model was applied to individual patient data meta-analyses in gastric cancer to assess disease-free survival as a surrogate for overall survival, as part of the evaluation of adjuvant therapy.
dc.language.isoENen_US
dc.subject.enBiostatistics
dc.title.enOne-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints
dc.title.alternativeStat Meden_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/sim.8162en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30997685en_US
bordeaux.journalStatistics in Medicineen_US
bordeaux.page2928-2942en_US
bordeaux.volume38en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue16en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamBIOSTAT_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03210794
hal.version1
hal.date.transferred2021-04-28T08:36:10Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Statistics%20in%20Medicine&rft.date=2019-07-20&rft.volume=38&rft.issue=16&rft.spage=2928-2942&rft.epage=2928-2942&rft.eissn=1097-0258%20(Electronic)%200277-6715%20(Linking)&rft.issn=1097-0258%20(Electronic)%200277-6715%20(Linking)&rft.au=SOFEU,%20Casimir&EMURA,%20T.&RONDEAU,%20Virginie&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée